Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Evaluation of the Efficacy and Safety of LW402 Tablets in Patients With Non-Segmental Vitiligo
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of LW402 Tablets in Patients With Non-Segmental Vitiligo
Status: Opening soon
Description:
This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to assess the efficacy, safety, and tolerability of LW402 tablets in participants with non-segmental vitiligo. Drawing on the prior/preclinical data of LW402 tablets, this clinical trial will incorporate three dose groups: 50 mg twice daily (BID), 100 mg BID, and 150 mg BID. The trial will be structured into a screening period (maximum 5 weeks), a treatment period (52 weeks, encompassing a 24-week main trial phase and a 28-week extension phase), and a safety follow-up period (4 weeks). The maximum duration of participation in this study will be 61 weeks. Following the completion of 24-week data collection for all trial participants, unblinding will be performed in accordance with the pre-specified procedure. Subsequently, based on the unblinded data results, regulatory communication will be conducted with the Center for Drug Evaluation (CDE) regarding the initiation of the Phase III confirmatory clinical trial. Participants who have undergone unblinding will continue to attend scheduled study visits to complete the trial.
Phase: Phase 2.
What is being studied: drugs — Experimental LW402 Tablet, Placebo.
Who can take part: ages 18 Years to 75 Years, 180 participants planned.
Enrollment status: Opening soon. The study started 31 May 2026 and is expected to finish 31 December 2028.
Contact: Barbara Chen.
Source: ClinicalTrials.gov, NCT07556471 (https://clinicaltrials.gov/study/NCT07556471).
Start date: May 31, 2026
Completion date: December 31, 2028
Organizer: Shanghai Longwood Biopharmaceuticals Co., Ltd.
Contact: Barbara Chen
Tel.: +86-21-63634910
Email: barbara@lwbiopharma.com
Clinical Trial Alerts
Sign up and be the first to know about updates on this trial.
FAQOther Questions
- Which is better for judging vitiligo — Wood’s lamp or dermoscopy?
A recent study out of India compared the two head-to-head. Both tools correlated fairly well with clinical criteria, but dermoscopy had a slight edge: Wood’s lamp: sensitivity 7...
- PTSD in Vitiligo?
Living with vitiligo often involves more than managing visible skin changes. Many individuals face discrimination, social stigma, and feelings of isolation, leading to emotional...
- What's better: laser or phototherapy?
Laser therapy is actually a type of phototherapy. Both rely on light to trigger changes in the skin, but they work differently. Phototherapy usually means a narrow-band UV (NB-U...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.